Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene.
Categories
Primary Antibodies
Cellular Localization
Widely
Clonality
polyclonal
Description
SNCA, also named as NACP, PARK1 and Alpha-synuclein, belongs to the synuclein family. It may be involved in the regulation of dopamine release and transport. SNCA reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. The deposition of aggregated SNCa is the pathological hallmark of Lewy body disease, which includes Parkinson's disease (PD), diffuse Lewy body disease (DLBD), and Lewy body variant of Alzheimer's disease (LBV).(PMID:21056999) This antibody can recognize all the isoforms of SNCA.
Host
Rabbit
Immunogen
synuclein, alpha (non A4 component of amyloid precursor)
Isotype
IgG
Molecular Weight
15 kDa
Reactivity
Human, Rat
Regulatory
RUO
Synonyms
Alpha synuclein, NACP, PARK1, PARK4, SNCA
Uniprot
P37840
Gene Id
6622
Research Area
Neuroscience
Weight
14kDa,observed 19kDa
Form
liquid
Format
liquid
Purification
Immunogen affinity purified
Purity
>=95% as determined by SDS-PAGE
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze / thaw cycles.)